SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
(NASDAQ: SPRC) Delayed: 4.51 +0.06 (1.35%)
Previous Close $4.45    52 Week High $ 
Open $4.48    52 Week Low $ 
Day High $4.64    P/E N/A 
Day Low $4.45    EPS $ 
Volume 3,058       

(NASDAQ: SPRC) Delayed: 4.51 +0.06 (1.35%)
Previous Close $4.45    52 Week High $ 
Open $4.48    52 Week Low $ 
Day High $4.64    P/E N/A 
Day Low $4.45    EPS $ 
Volume 3,058